Cortisone Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Cortisone Market Trends and Insights

Rising Burden of Osteoarthritis, Rheumatoid Arthritis and Gout

Joint and connective tissue disorders remained a key demand driver for the cortisone market. The CDC reported that 25.7 million of the 58.5 million US adults with arthritis experienced activity limitations due to the condition and projected that 34.6 million adults would have activity-limiting arthritis by 2040. Corticosteroids played a short-term role in controlling disease activity before disease-modifying therapies became fully effective. Acute gout also supported demand when colchicine or nonsteroidal anti-inflammatory drugs were unsuitable.

Growth in Adrenal-Insufficiency Diagnosis and Replacement Therapy

Newborn screening and improved diagnostic practices expanded the treated population for congenital adrenal hyperplasia and adrenal insufficiency. Screening programs used 17-hydroxyprogesterone testing to identify infants with classic congenital adrenal hyperplasia at birth, creating a need for lifelong glucocorticoid replacement. The FDA approved crinecerfont in December 2024 as an adjunct treatment for classic congenital adrenal hyperplasia, to be used alongside glucocorticoid replacement. A 2025 review identified modified-release hydrocortisone and CRF1 antagonists as major developments that reduced steroid exposure while maintaining adrenal control.

Preference for Rapid and Low-Cost Anti-Inflammatory Treatment

Cortisone remained a cost-effective option for rapid anti-inflammatory treatment. Clinicians used it for acute gout, bursitis, severe allergic reactions, perioperative stress dosing, and other corticosteroid-responsive conditions. Demand remained strong in Middle Eastern, African, and South American healthcare settings, where affordability influenced prescribing and reimbursement limited access to higher-cost biologics. Hospital procurement agreements also supported recurring purchases of generic cortisone acetate despite declining unit prices.

Expansion of Outpatient Orthopedic and Sports-Medicine Procedures

Outpatient orthopedic, rheumatology, and sports medicine settings increasingly delivered musculoskeletal care. This shift expanded access to corticosteroid injections for joint and soft-tissue conditions. Ultrasound-guided procedures improved injection accuracy in complex joints, including the hip, shoulder, and sacroiliac region. Growing ambulatory orthopedic activity supported local injection volumes outside inpatient hospital settings, expanding the procedural base for the cortisone market.

Adverse Effects Associated with Cumulative Glucocorticoid Exposure

Safety concerns related to prolonged glucocorticoid use limit cortisone use in chronic care. A 2024 clinical review reported that 30% of long-term users developed secondary osteoporosis, while 30% to 50% of patients receiving extended treatment experienced fractures. Glucocorticoid users also faced a 160% to 185% higher spinal-fracture risk than healthy non-users. European guidelines recommended bone-risk assessments and preventive treatment for patients receiving 7.5 mg per day or more, supporting a shift toward steroid-sparing therapies and reducing the potential for long-term repeat prescribing in the Cortisone market.

Competition, Price Erosion, and Supply Vulnerability

Hydrocortisone, prednisolone, extended-release hydrocortisone, biologics, and JAK inhibitors competed with cortisone across treatment settings. Hydrocortisone remained important for physiologic adrenal replacement, while prednisolone was selected for predictable oral use in inflammatory conditions. The FDA approved KHINDIVI, a hydrocortisone oral solution for pediatric patients aged 5 years and older with adrenocortical insufficiency, in May 2025. Generic competition reduced cortisone acetate revenue per unit, while concentrated low-volume steroid active pharmaceutical ingredient production increased supply vulnerability, favoring suppliers with strong quality, regulatory compliance, and supply capabilities.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Cortisone Acetate Supports Revenue while Phosphate Salts Lead Growth

Cortisone Acetate accounted for 56.45% of product-type revenue in 2025, making it the primary revenue contributor in the cortisone market. Established oral protocols, broad generic formulary inclusion, and continued replacement use support demand. Generic competition has reduced acquisition costs, sustaining volumes despite pressure on manufacturer margins. Familiar dosing and broad availability reinforce its use in treatment pathways that prioritize reliable access.

Cortisone Sodium Phosphates are projected to grow at a CAGR of 9.23% from 2026 to 2031, the highest rate among product types. Water solubility supports intravenous administration in hospital, critical-care, and perioperative settings. Demand for ready-to-use formulations is increasing, particularly for adrenal crisis and severe anaphylaxis protocols. Suspension and compounded products retain smaller roles in dermatological and ophthalmic applications.

By Dosage Form: Injectable Preparations Lead while Oral Tablets Grow Fastest

Injectable Preparations accounted for 54.34% of dosage-form revenue in 2025, representing the largest dosage-form segment in the cortisone market. They support intra-articular, intramuscular, and intravenous administration across rheumatology, orthopedics, emergency medicine, and critical care. Recurring hospital and specialty-clinic procurement arrangements help stabilize demand. Injectable products remain important when rapid treatment is required or oral administration is unsuitable.

Oral Tablets are projected to grow at a CAGR of 8.88% from 2026 to 2031, the fastest rate among dosage forms. Growth is driven by outpatient chronic-disease management, dose tapering, and replacement therapy for congenital adrenal hyperplasia and adrenal insufficiency. Modified-release products provide more tailored dosing, although availability varies by country. A 2025 study of 790 patients found that modern glucocorticoid therapies had reached only 5% of the observed congenital adrenal hyperplasia cohort by 2023. Immediate-release tablets remain important as affordable options for outpatient tapering schedules.

By Route of Administration: Local Injection Leads while Intramuscular Use Gains Momentum

Intra-Articular and Local Injection accounted for 45.88% of route-of-administration revenue in 2025. This route is widely used to treat osteoarthritis, inflammatory arthritis, bursitis, and tendinitis. Ultrasound-guided administration has improved targeting in anatomically complex locations and supports outpatient procedures. Local administration can also limit systemic exposure in patients with focal pain or inflammation.

The Intramuscular Route is projected to grow at a CAGR of 10.55% from 2026 to 2031, the fastest rate among administration routes. Depot injections support single-dose treatment for patients with poor adherence to oral regimens or limited intravenous access. In June 2025, Hikma launched Triamcinolone Acetonide Injectable Suspension, USP, 40 mg/mL, in the United States as its first complex injectable corticosteroid suspension in the country. The product was approved for inflammatory, autoimmune, hormonal, and other corticosteroid-responsive conditions. Clinic-administered depot treatments can reduce adherence challenges associated with repeated oral dosing.

By Therapeutic Application: Rheumatic Disease Leads while Adrenal Indications Expand Fastest

Rheumatoid and Psoriatic Arthritis accounted for 47.23% of therapeutic-application revenue in 2025. Corticosteroids remain important for short-course disease control while longer-acting disease-modifying therapies take effect. Osteoarthritis, bursitis, and tendinitis form the next major indication group, supported by aging patient populations and greater availability of ambulatory injection procedures. Disease severity, affected joints, prior therapy, and the need for prompt symptom control influence treatment selection.

Adrenal Insufficiency and Congenital Adrenal Hyperplasia are projected to grow at a CAGR of 11.34% through 2031. Newborn screening and improved adult diagnosis are expanding the number of patients receiving long-term replacement therapy. A 2025 Nature Reviews Endocrinology article described combination approaches using CRF1 antagonists and glucocorticoids to reduce steroid doses while maintaining replacement coverage. Dermatological, respiratory, allergic, ophthalmic, hematological, and neoplastic disorders also contribute to demand. Interest in low-dose regimens is increasing to balance clinical control with cumulative glucocorticoid exposure.

By End User: Hospitals Lead while Specialty Clinics Build Their Role

Hospitals accounted for 53.13% of end-user revenue in 2025, giving them the leading position in the cortisone market. They manage acute and complex inflammatory conditions that often require injectable treatments, critical-care protocols, and multidisciplinary support. Formal procurement processes for injectable corticosteroids create predictable volume demand for suppliers with reliable availability. Hospitals remain critical for emergency treatment, including adrenal crisis and severe allergic reactions.

Specialty Clinics are projected to grow at a CAGR of 8.45% from 2026 to 2031, the highest rate among end-user settings. Rheumatology, endocrinology, dermatology, and sports-medicine practices serve concentrated patient populations requiring corticosteroid treatment. Endocrinology clinics are positioned to benefit as screening identifies more congenital adrenal hyperplasia and adrenal insufficiency cases. Homecare, physician offices, primary-care practices, and ambulatory surgical centers continue to expand their role as care shifts toward outpatient settings.

Geography Analysis

North America held 41.66% of global revenue in 2025 and was the largest regional contributor to the Cortisone market. High diagnosis rates for arthritis and autoimmune diseases, reimbursement support for injectable procedures and oral corticosteroids, and established specialist networks in the United States drove regional demand. Canada added volume through provincial public drug formularies, while Mexico emerged as the fastest-growing national opportunity due to expanding private clinic capacity, a large working-age population, and rising demand for musculoskeletal injury treatment. Suppliers addressed this demand through clinic-focused distribution and affordable injectable offerings.

Asia-Pacific was forecast to grow at a CAGR of 11.65% through 2031, the fastest regional growth rate in the Cortisone market. China remained a major corticosteroid active pharmaceutical ingredient production base, while India combined export-oriented manufacturing with growing domestic demand. Japan, South Korea, Vietnam, Indonesia, and Thailand offered growth potential through aging populations, increasing healthcare access, and improving specialist density.

The Middle East and Africa remained constrained by affordability, although health infrastructure investment in Saudi Arabia and the United Arab Emirates improved access to essential corticosteroid treatment. Suppliers needed to balance cost-competitive offerings, reliable supply, regulatory compliance, product registrations, distribution capacity, and pricing across varied reimbursement systems. These conditions favored lower-cost generic products in some markets and differentiated formulations in others.